The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

In this week’s edition of The Prototype, we look at quantum computing for image recognition, a gene therapy using a patient’s ...

HMTM previously failed a phase 3 trial reported in 2016, and it remains to be seen whether the FDA will be swayed the LUCIDITY data without a comparison to control, especially given the ...